Induction of bone resorption by parathyroid hormone in congenital malignant osteopetrosis.
A male patient, afflicted with malignant congenital osteopetrosis, was studied over a 5 year period. Hypocalcemia (less than 8 mg/dl) with lack of an appropriate increase in serum immunoreactive parathyroid hormone (iPTH) prevailed at all times. Under a calcium restricted diet, a 6-hour infusion of parathyroid extract normalized serum calcium, and increased the urinary hydroxyproline excretion suggesting that bone resorption had been induced. A second attempt to induce resorption was made by infusing a synthetic amino terminal fragment of bovine PTH over a period of 3 weeks at the dose of 1.5 units/kg/hr. This infusion evoked an increase in serum calcium (8.1 to 10.5 mg/dl), urinary calcium (0.03 to 0.65 mg/g creatinine) and urinary hydroxyproline (160 to 372 mg/g creatinine); and urinary hydroxyproline (160 to 372 mg/g creatinine); increases which were reversed by calcitonin administration. Iliac crest bone biopsies were obtained before and on the last day of the 3-week infusion. Quantitative comparison of the two specimens showed that, during PTH infusion, there was a 23% decrease in bone volume due to the increase in marrow space, a 93% increase in the number of osteoclasts and 136% increment in the osteoclastic resorption surface. Electron microscopic examination of the osteoclasts in the first tissue sample showed no evidence of ruffled borders, while in the second biopsy, numerous cytoplasmic processes indicative of resorptive activity were visible at the matrix-cell interface. It is proposed that, in our patient, the osteopetrotic phenotype is the consequence of an abnormality in the interaction between PTH and osteoclasts that may be related to the synthesis of a physiologically "defective" PTH.
D015652:25-Hydroxyvitamin D 2; D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption / Q000187:drug effects*; D001842:Bone and Bones / Q000473:pathology; D002116:Calcitonin; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000378:metabolism; D002648:Child; D004872:Ergocalciferols / Q000031:analogs & derivatives / Q000097:blood; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D010022:Osteopetrosis / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010710:Phosphates / Q000652:urine
D004872:Ergocalciferols; D010281:Parathyroid Hormone; D010710:Phosphates; D015652:25-Hydroxyvitamin D 2; D002116:Calcitonin; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002118:Calcium